Not unaccustomed to accolades and honors, Prof. Arnon Nagler was yet again recognized for his expertise and clinical excellence: this time by Forbes magazine, which named him one of Israel’s leading hematologists.
A pioneer of non-myeloablative and reduced intensity\toxicity allogeneic transplantations for both malignant and non-malignant tumors, Prof. Nagler has published hundreds of articles, reviews, and chapters in premier peer-reviewed journals, and has served as head of Sheba’s hematological array for the past 20 years. Notwithstanding, Prof. Nagler also maintains a senior teaching position at Tel-Aviv University, and has held prominent leadership positions in international cancer organizations throughout his extensive career.
Upon learning of this latest honor, Prof. Nagler offered the following remarks: “allogeneic transplantations and cell immunotherapy are at the cutting-edge of cancer care and constitute life-saving treatments for many patients. I am truly grateful for the privilege to dedicate my professional life towards developing these therapies.”
